News

Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy

The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition

NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis and management of heart failure, and risk stratification of patients with acute

Biosound Esaote joins Acuson, a Siemens company, Royal Philips Electronics and General Electric as a licensee of the tissue harmonic imaging (THI) technology. Shaun Kirkpatrick, president and CEO

The existing agreement with Janssen Pharmaceutica already covers the EU, Eastern Europe, Russia, the Middle-East and Africa. All the commercial and contractual conditions remain in effect. The product

ENMD-2076 is a novel, dual-acting, kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. The company claims that ENMD-2076

Watson’s Clarithromycin extended-release product is the generic equivalent to Abbott’s Biaxin XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be

The Phase II randomized, controlled open-label study enrolled a total of 67 patients with mildly infected diabetic foot ulcers at 15 US sites. Three treatment arms were evaluated:

The company expects to raise an additional $1.8 million in a second tranche, which is scheduled to close on February 29, 2008, resulting in total net proceeds of